Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 06 Apr 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2025.
- 25 Nov 2020 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
- 03 Mar 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.